LinkedIn Profile

Access Endo International historical Linkedin company profile data on number of followers, employee headcount and more

Records

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:endp 11485 Sep 20th, 2019 12:00AM Endo Pharmaceuticals 42K 1792 Open Pharmaceuticals Sep 20th, 2019 08:24AM Sep 20th, 2019 08:24AM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 19th, 2019 12:00AM Endo Pharmaceuticals 42K 1793 Open Pharmaceuticals Sep 18th, 2019 10:21PM Sep 18th, 2019 10:21PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 18th, 2019 12:00AM Endo Pharmaceuticals 42K 1790 Open Pharmaceuticals Sep 18th, 2019 12:26PM Sep 18th, 2019 12:26PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 17th, 2019 12:00AM Endo Pharmaceuticals 42K 1790 Open Pharmaceuticals Sep 16th, 2019 10:23PM Sep 16th, 2019 10:23PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 16th, 2019 12:00AM Endo Pharmaceuticals 42K 1789 Open Pharmaceuticals Sep 16th, 2019 12:54PM Sep 16th, 2019 12:54PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 15th, 2019 12:00AM Endo Pharmaceuticals 42K 1789 Open Pharmaceuticals Sep 14th, 2019 10:22PM Sep 14th, 2019 10:22PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 14th, 2019 12:00AM Endo Pharmaceuticals 42K 1789 Open Pharmaceuticals Sep 14th, 2019 02:56PM Sep 14th, 2019 02:56PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 13th, 2019 12:00AM Endo Pharmaceuticals 42K 1787 Open Pharmaceuticals Sep 13th, 2019 02:56PM Sep 13th, 2019 02:56PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 12th, 2019 12:00AM Endo Pharmaceuticals 42K 1788 Open Pharmaceuticals Sep 11th, 2019 10:21PM Sep 11th, 2019 10:21PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology
nasdaq:endp 11485 Sep 11th, 2019 12:00AM Endo Pharmaceuticals 42K 1789 Open Pharmaceuticals Sep 11th, 2019 12:21PM Sep 11th, 2019 12:21PM Endo International plc is a highly focused generics and specialty pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Endo’s strategy is to centralize and unify our business, driving productivity improvements. We will focus on organic growth by investing in hard-to-produce generic assets & technologies and transforming the branded business into a highly focused Specialty business. Additionally, we are concentrating on differentiated and intelligent product selection to shape our company for long-term success. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. We employ approximately 3,000 people worldwide*. For more information about Endo International and our operating companies, please visit www.endo.com. *as of 03/30/2018 Open urology, men’s health, orthopedics and endocrinology, with product development underway in medical aesthetics. Open 1400 Atwater Drive Malvern PA US 19355 Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.